Unveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer’s Disease
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Early and accurate diagnosis of AD is crucial for implementing timely interventions and developing effective therapeutic strategies. Proteome-based biomarkers have eme...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Proteomes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-7382/11/4/33 |
| _version_ | 1797379549899522048 |
|---|---|
| author | Mukul Jain Rupal Dhariwal Nil Patil Sandhya Ojha Reshma Tendulkar Mugdha Tendulkar Parmdeep Singh Dhanda Alpa Yadav Prashant Kaushik |
| author_facet | Mukul Jain Rupal Dhariwal Nil Patil Sandhya Ojha Reshma Tendulkar Mugdha Tendulkar Parmdeep Singh Dhanda Alpa Yadav Prashant Kaushik |
| author_sort | Mukul Jain |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Early and accurate diagnosis of AD is crucial for implementing timely interventions and developing effective therapeutic strategies. Proteome-based biomarkers have emerged as promising tools for AD diagnosis and prognosis due to their ability to reflect disease-specific molecular alterations. There is of great significance for biomarkers in AD diagnosis and management. It emphasizes the limitations of existing diagnostic approaches and the need for reliable and accessible biomarkers. Proteomics, a field that comprehensively analyzes the entire protein complement of cells, tissues, or bio fluids, is presented as a powerful tool for identifying AD biomarkers. There is a diverse range of proteomic approaches employed in AD research, including mass spectrometry, two-dimensional gel electrophoresis, and protein microarrays. The challenges associated with identifying reliable biomarkers, such as sample heterogeneity and the dynamic nature of the disease. There are well-known proteins implicated in AD pathogenesis, such as amyloid-beta peptides, tau protein, Apo lipoprotein E, and clusterin, as well as inflammatory markers and complement proteins. Validation and clinical utility of proteome-based biomarkers are addressing the challenges involved in validation studies and the diagnostic accuracy of these biomarkers. There is great potential in monitoring disease progression and response to treatment, thereby aiding in personalized medicine approaches for AD patients. There is a great role for bioinformatics and data analysis in proteomics for AD biomarker research and the importance of data preprocessing, statistical analysis, pathway analysis, and integration of multi-omics data for a comprehensive understanding of AD pathophysiology. In conclusion, proteome-based biomarkers hold great promise in the field of AD research. They provide valuable insights into disease mechanisms, aid in early diagnosis, and facilitate personalized treatment strategies. However, further research and validation studies are necessary to harness the full potential of proteome-based biomarkers in clinical practice. |
| first_indexed | 2024-03-08T20:24:53Z |
| format | Article |
| id | doaj.art-4566b31177b04e359e411da3529e8e85 |
| institution | Directory Open Access Journal |
| issn | 2227-7382 |
| language | English |
| last_indexed | 2024-03-08T20:24:53Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Proteomes |
| spelling | doaj.art-4566b31177b04e359e411da3529e8e852023-12-22T14:37:57ZengMDPI AGProteomes2227-73822023-10-011143310.3390/proteomes11040033Unveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer’s DiseaseMukul Jain0Rupal Dhariwal1Nil Patil2Sandhya Ojha3Reshma Tendulkar4Mugdha Tendulkar5Parmdeep Singh Dhanda6Alpa Yadav7Prashant Kaushik8Cell and Developmental Biology Laboratory, Research and Development Cell, Parul University, Vadodara 391760, IndiaCell and Developmental Biology Laboratory, Research and Development Cell, Parul University, Vadodara 391760, IndiaCell and Developmental Biology Laboratory, Research and Development Cell, Parul University, Vadodara 391760, IndiaDepartment of Life Sciences, Parul Institute of Applied Sciences, Parul University, Vadodara 391760, IndiaVivekanand Education Society, College of Pharmacy, Chembur, Mumbai 400071, IndiaSardar Vallabhbhai Patel College of Science, Mira Rd (East), Thane 400071, IndiaDepartment of Biochemistry, Punjab Agricultural University, Ludhiana 141027, IndiaDepartment of Botany, Indira Gandhi University, Meerpur, Rewari 122502, IndiaInstituto de Conservacióny Mejora de la Agrodiversidad Valenciana, Universitat Politècnica de València, 46022 Valencia, SpainAlzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Early and accurate diagnosis of AD is crucial for implementing timely interventions and developing effective therapeutic strategies. Proteome-based biomarkers have emerged as promising tools for AD diagnosis and prognosis due to their ability to reflect disease-specific molecular alterations. There is of great significance for biomarkers in AD diagnosis and management. It emphasizes the limitations of existing diagnostic approaches and the need for reliable and accessible biomarkers. Proteomics, a field that comprehensively analyzes the entire protein complement of cells, tissues, or bio fluids, is presented as a powerful tool for identifying AD biomarkers. There is a diverse range of proteomic approaches employed in AD research, including mass spectrometry, two-dimensional gel electrophoresis, and protein microarrays. The challenges associated with identifying reliable biomarkers, such as sample heterogeneity and the dynamic nature of the disease. There are well-known proteins implicated in AD pathogenesis, such as amyloid-beta peptides, tau protein, Apo lipoprotein E, and clusterin, as well as inflammatory markers and complement proteins. Validation and clinical utility of proteome-based biomarkers are addressing the challenges involved in validation studies and the diagnostic accuracy of these biomarkers. There is great potential in monitoring disease progression and response to treatment, thereby aiding in personalized medicine approaches for AD patients. There is a great role for bioinformatics and data analysis in proteomics for AD biomarker research and the importance of data preprocessing, statistical analysis, pathway analysis, and integration of multi-omics data for a comprehensive understanding of AD pathophysiology. In conclusion, proteome-based biomarkers hold great promise in the field of AD research. They provide valuable insights into disease mechanisms, aid in early diagnosis, and facilitate personalized treatment strategies. However, further research and validation studies are necessary to harness the full potential of proteome-based biomarkers in clinical practice.https://www.mdpi.com/2227-7382/11/4/33Alzheimer’s diseasebiomarkersproteomicsmicroarraybioinformatics |
| spellingShingle | Mukul Jain Rupal Dhariwal Nil Patil Sandhya Ojha Reshma Tendulkar Mugdha Tendulkar Parmdeep Singh Dhanda Alpa Yadav Prashant Kaushik Unveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer’s Disease Proteomes Alzheimer’s disease biomarkers proteomics microarray bioinformatics |
| title | Unveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer’s Disease |
| title_full | Unveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer’s Disease |
| title_fullStr | Unveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer’s Disease |
| title_full_unstemmed | Unveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer’s Disease |
| title_short | Unveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer’s Disease |
| title_sort | unveiling the molecular footprint proteome based biomarkers for alzheimer s disease |
| topic | Alzheimer’s disease biomarkers proteomics microarray bioinformatics |
| url | https://www.mdpi.com/2227-7382/11/4/33 |
| work_keys_str_mv | AT mukuljain unveilingthemolecularfootprintproteomebasedbiomarkersforalzheimersdisease AT rupaldhariwal unveilingthemolecularfootprintproteomebasedbiomarkersforalzheimersdisease AT nilpatil unveilingthemolecularfootprintproteomebasedbiomarkersforalzheimersdisease AT sandhyaojha unveilingthemolecularfootprintproteomebasedbiomarkersforalzheimersdisease AT reshmatendulkar unveilingthemolecularfootprintproteomebasedbiomarkersforalzheimersdisease AT mugdhatendulkar unveilingthemolecularfootprintproteomebasedbiomarkersforalzheimersdisease AT parmdeepsinghdhanda unveilingthemolecularfootprintproteomebasedbiomarkersforalzheimersdisease AT alpayadav unveilingthemolecularfootprintproteomebasedbiomarkersforalzheimersdisease AT prashantkaushik unveilingthemolecularfootprintproteomebasedbiomarkersforalzheimersdisease |